Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Insider Transactions

Date Name Title Type Shares Traded Price Range
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 8,000 $0.01
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 3,000 $0.01
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 450,000 $1.15
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 300,000 $1.15
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 10,000 $0.01
Jan 16, 2009
Vice President Finance
Vice President Finance Grant, award or other acquisition pursuant to Rule 16b-3(d) 50,000 $1.47
Jan 16, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 350,000 $1.47
Dec 31, 2008
Director, Chairman, CEO & President
Director, Chairman, CEO & President Bona fide gift 12,370 $1.94
Dec 06, 2008
Vice President Finance
Vice President Finance Grant, award or other acquisition pursuant to Rule 16b-3(d) 50,000 $1.43
Dec 06, 2008
Vice President Finance
Vice President Finance Grant, award or other acquisition pursuant to Rule 16b-3(d) 30,000 --
Dec 06, 2008
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 200,000 --
Dec 06, 2008
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 150,000 $1.43
Oct 30, 2008
Chief Scientific Officer
Chief Scientific Officer Open market or private sale of non-derivative or derivative security 5,000 $1.82
Oct 30, 2008
Chief Scientific Officer
Chief Scientific Officer Open market or private sale of non-derivative or derivative security 5,000 $1.60
Jul 15, 2008
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 7,500 $1.44
Jun 26, 2008
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 4,900 $1.35
Jun 26, 2008
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 5,100 $1.33
Jun 25, 2008
Chief Scientific Officer
Chief Scientific Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 100 $1.48
Jun 25, 2008
Chief Scientific Officer
Chief Scientific Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 10,000 $1.40
Jun 25, 2008
Chief Scientific Officer
Chief Scientific Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 5,000 $1.39
Jun 25, 2008
Chief Scientific Officer
Chief Scientific Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 5,000 $1.33
Jun 25, 2008
Chief Scientific Officer
Chief Scientific Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 10,000 $1.41
Jun 24, 2008
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 10,000 $1.43
Jun 23, 2008
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 2,500 $1.50
Jun 23, 2008
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 11,400 $1.45

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright Nasdaq. Minimum 15 minutes delayed.